Document is current
Any future updates will be listed below
-
Authors
Maleki Balajoo, Somayeh
Rahmani, Farzaneh
Khosrowabadi, Reza
Meng, Chun
Eickhoff, Simon B.
Grimmer, Timo
Zarei, Mojtaba
Drzezga, Alexander
Sorg, Christian
Tahmasian, Masoud https://orcid.org/0000-0003-3999-3807
-
Funding
Funding for this research was provided by:
Forschungszentrum Jülich GmbH
- License Information
-
More Information
Article History
Received: 17 August 2021
Accepted: 13 January 2022
First Online: 24 February 2022
Declarations
:
: This study was approved by the TUM ethics committee in line with the institute’s Human Research Committee guidelines and conformed to standards of the declaration of Helsinki.
: Written informed consent was obtained from all participants after providing detailed information about this study.
: A. Drzezga declares the following conflict of interest: research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, and SOFIE; speaker honorary/advisory boards: Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, Invicro; stock: Siemens Healthineers, Lantheus Holding, Biogen; patents: patent pending for 18F-PSMA7 (PSMA PET imaging tracer). Outside the submitted manuscript, T. Grimmer received consulting fees from Abbvie, Anavex, Biogen, Bracket, Eli Lilly, Functional Neuromodulation, Grifols, IQVIA/Quintiles, Novartis, Novo Nordisk, Noselab, NuiCare, Roche Pharma, Toyama, and Vivoryon; lecture fees from Actelion, B. Braun, Biogen, Eli Lilly, Life Molecular Imaging, Novartis, Parexel, and Roche Pharma; and grants to his institution from Actelion and Novartis. The other authors declare no competing interests.
